KMPH - ケムファ―ム （KemPharm Inc.）

https://www.investing.com/news/assorted/kempharm-files-preliminary-proxy-432SI-3016191

https://www.investing.com/news/assorted/kempharm-announces-arimoclomol-research-featured-in-two-poster-presentations-432SI-3013822

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered,

We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined +40%, and now the stock is trading at an attractive enterprise value of $130m. Read more here.

KemPharm Inc. (NASDAQ:KMPH) marked $5.61 per share on Tuesday, down from a previous closing price of $6.27. While KemPharm Inc. has underperformed by -10.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KMPH fell by -13.43%, with highs and lows ranging from $7.38 to $4.00, whereas […]

https://www.investing.com/news/assorted/kempharm-files-preliminary-proxy-432SI-3016191

https://www.investing.com/news/assorted/kempharm-announces-arimoclomol-research-featured-in-two-poster-presentations-432SI-3013822

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered,

We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined +40%, and now the stock is trading at an attractive enterprise value of $130m. Read more here.

KemPharm Inc. (NASDAQ:KMPH) marked $5.61 per share on Tuesday, down from a previous closing price of $6.27. While KemPharm Inc. has underperformed by -10.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KMPH fell by -13.43%, with highs and lows ranging from $7.38 to $4.00, whereas […]

Full story available on Benzinga.com

KemPharm, Inc. (KMPH), a company developing prodrug versions of FDA-approved drugs, announced Wednesday early results from a Phase 1 trial to support further studies for lead asset…

U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. The Dow traded down 0.12% to 31,099.20 while the NASDAQ fell 1.18% to 11,581.65. The S&P 500 also fell, dropping, 0.71% to 3,918.10. Also check this: Ethereum Records Gains; Here Are The Top Crypto Movers For Thursday Leading and Lagging Sectors Health care shares climbed 0.7% on Thursday. Meanwhile, top gainers in the sector included Armata Pharmaceuticals, Inc. (NYSE: ARMP ), up 10% and KemPharm, Inc. (NASDAQ: KMPH ) up 9%. In trading on Thursday, information technology shares fell by 2.2%. Top Headline U.S. retail sales increased 0.3% in August from July, versus a revised 0.4% decline in the prior month and topping market expectations for a flat reading. Equities Trading UP ZW Data Action Technologies Inc. (NASDAQ: CNET ) shares shot up 44% to $0.9549. ZW Data Action Technologies reported planned acquisition of Henan Baodun. Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO ) got a boost, shooting 36% to $22.96 after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty hepatitis to NeuroBo.

Canaccord Genuity has launched its coverage on KemPharm, Inc

CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24 th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York. In addition, management will be available for virtual one-on-one investor meetings during the conference.